| US 7,615,554 B2 | ||
| Erastin and erastin binding proteins, and uses thereof | ||
| Robert Selliah, Midvale, Utah (US); Longwu Qi, Salt Lake City, Utah (US); Paul B. Robbins, Park City, Utah (US); Sudhir R. Sahasrabudhe, Sandy, Utah (US); Brent R. Stockwell, New York, N.Y. (US); and Raj Gopal Venkat, Salt Lake City, Utah (US) | ||
| Assigned to Prolexys Pharmaceuticals, Inc., Salt Lake City, Utah (US); Whitehead Institute for Biomedical Research, Cambridge, Mass. (US); and The Trustees of Columbia University in the City of New York, New York, N.Y. (US) | ||
| Filed on Jan. 25, 2006, as Appl. No. 11/340,430. | ||
| Claims priority of provisional application 60/762221, filed on Jan. 24, 2006. | ||
| Claims priority of provisional application 60/647303, filed on Jan. 25, 2005. | ||
| Prior Publication US 2006/0211683 A1, Sep. 21, 2006 | ||
| Int. Cl. A61K 31/497 (2006.01); A01N 43/62 (2006.01); C07D 243/08 (2006.01); C07D 239/72 (2006.01) | ||
| U.S. Cl. 514—252.17 [514/218; 540/575; 544/287] | 23 Claims |
1. A compound having a structure of Formula V or a pharmaceutically acceptable salt thereof,
 R1 is selected from H and C1-8 alkyl;
R2 is selected from H and C1-8 alkyl wherein C1-8-alkyl is optionally substituted by one or more of hydroxyl, halo, cyano, alkoxy, nitro, carbonyl, thiocarbonyl, phosphoryl,
phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl,
sulfamido, sulfonyl and heterocyclyl;
R3 is selected from alkoxy and unsubstituted C1-8alkyl;
R4 is selected from H, alkoxy and unsubstituted C1-8alkyl;
R5 is selected from H, halogen; and
n is 1 or 2.
|